2025 - WEEK 5 - What's New in RWE Research
- Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study. Khare S, Osumili B, Debackere N, Keapoletswe K, Falato S, Raoul T, Coles B. Adv Ther. 2025 Jan;42(1):174-192
- Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study. Rannikko A, Hölsä O, Ågesen T, Ekman M, Mattila R. Acta Oncol. 2025 Jan 29;64:173-178.
- Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries. Ciurea A, Kissling S, Götschi A, Ørnbjerg LM, Rasmussen SH, Tamási B, Möller B, Nissen MJ, Glintborg B, Loft AG, Scherer A, Bräm R, Pavelka K, Závada J, Dias JM, Valente P, Gudbjornsson B, Palsson O, Rantalaiho V, Peltomaa R, Codreanu C, Mogosan C, Iannone F, Sebastiani M, Jones GT, Macfarlane GJ, Castrejon I, Rotar Z, Michelsen B, Wallman JK, van der Horst-Bruinsma I, Distler O, Østergaard M, Hetland ML, Micheroli R, Ospelt C. Arthritis Res Ther. 2025 Jan 31;27(1):18.
- Expert navigators deploy rational complexity-based decision precaching for large-scale real-world planning. Fernandez Velasco P, Griesbauer EM, Brunec IK, Morley J, Manley E, McNamee DC, Spiers HJ.Proc Natl Acad Sci U S A. 2025 Jan 28;122(4):e2407814122.
- Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark - A national registry study. Larsen CS, Westergaard CL, Stærke NB, Arnet U, Liu G, Kantsø LR, Kjellberg J.Antivir Ther. 2025 Feb;30(1):13596535241313244.
- Real-World Evaluation of i-gel Introduction on Intraoperative Airway-Related Safety Events: A Retrospective Cohort Study From a New England Hospital Network. Obeidat SS, Suleiman A, Ahrens E, Needham MJ, Stewart C, Khany M, Tartler TM, Zucco L, Pandit JJ, Schaefer MS, Ramachandran SK. Anesth Analg. 2025 Feb 1;140(2):253-261.
- Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing. Maroselli P, Fanciullino R, Colle J, Farnault L, Roche P, Venton G, Costello R, Ciccolini J. Fundam Clin Pharmacol. 2025 Feb;39(1):e13049.
- The Utility of a Digital Glucose-Like Peptide-1 Receptor Agonist-Supported Weight-Loss Service in Regional Australia: A Qualitative Analysis of Interviews With Current Patients of the Eucalyptus Program. Talay L, Vickers M, Loftus S. Aust J Rural Health. 2025 Feb;33(1):e13220.
- Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population-based cohort study. Yu YH, Platt RW, Reynier P, Yu OHY, Filion KB. Diabetes Obes Metab. 2025 Feb;27(2):976-986.
- Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study. Niedersuess-Beke D, Mayrhofer K, Krauter J, Schnabel S, Gampenrieder SP, Miechowiecki J, Kiesl D, Luger F, Pfuner J, Wiesinger C, Vallet S, Andalibi H, Vais D, Banner A, Stoiber F, Spielgelberg J, Barth D, Bauernhofer T, Aufderklamm S, Weibrecht S, Mühlmann J, Mayer M, Hilbe W, Boulmé F, Klinglmair G, Heintel D, Shariat SF, Pichler M, Pichler R. Clin Genitourin Cancer. 2025 Feb;23(1):102278.
- Evaluating the Benefit of Home Support Provider Services for Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea: Protocol for an Ambispective International Real-World Study. Alami S, Schaller M, Blais S, Taupin H, Hernández González M, Gagnadoux F, Pinto P, Cano-Pumarega I, Bedert L, Braithwaite B, Servy H, Ouary S, Fabre C, Bazin F, Texereau J. JMIR Res Protoc. 2025 Jan 31;14:e65840.
- Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study. Tyrer F, Gharibzadeh S, Gillies C, Lawson C, Routen A, Islam N, Razieh C, Zaccardi F, Yates T, Davies MJ, Brightling CE, Chalmers JD, Docherty AB, Elneima O, Evans RA, Greening NJ, Harris VC, Harrison EM, Ho LP, Horsley A, Houchen-Wolloff L, Leavy OC, Lone NI, Marks M, McAuley HJC, Poinasamy K, Quint JK, Raman B, Richardson M, Saunders R, Sereno M, Shikotra A, Singapuri A, Wain LV, Khunti K; PHOSP‐COVID Study Collaborative Group. Diabetes Obes Metab. 2025 Feb;27(2):767-776.
- Case-fatality rate of invasive pneumococcal disease caused by various serotypes-an analysis of nationwide surveillance data from Israel, 2009-2018. Wieder-Finesod A, Yahav D, Rubin C, Hashkor S, Southern J, Mircus G, Theilacker C, Dagan R, Regev-Yochay G; Israeli Adult Invasive Pneumococcal Disease (IAIPD) Group.Clin Microbiol Infect. 2025 Feb;31(2):226-232.
- Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria. Golomb RC, Tittel SR, Welters A, Karges W, Meyhöfer S, Hummel M, Mader JK, Kämmer JC, Schloot NC, Holl RW. Diabetes Obes Metab. 2025 Feb;27(2):563-573.
- Isometric handgrip versus aerobic exercise: a randomized trial evaluating central and ambulatory blood pressure outcomes in older hypertensive participants. Jae SY, Yoon ES, Kim HJ, Cho MJ, Choo J, Kim JY, Kunutsor SK. J Hypertens. 2025 Feb 1;43(2):351-358.
- Real-world study on disease burden and current clinical practice of hospital-acquired pneumonia in Japan. Kimata M, Aoki Y, Akiyama T, Harada A.J Infect Chemother. 2025 Feb;31(2):102551.
- Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia. Chen EY, Dahlén T, Stenke L, Björkholm M, Hao S, Dickman PW, Clements MS.Eur J Haematol. 2025 Feb;114(2):334-342.
- Eculizumab in refractory myasthenia gravis: a real-world single-center experience. Ricciardi D, Erra C, Tuccillo F, De Martino BM, Fasolino A, Habetswallner F.Neurol Sci. 2025 Feb;46(2):951-959.
- Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease. DeBonnett L, Joshi V, Silva-Pinto AC, Colombatti R, Pasanisi A, Arcioni F, Cançado RD, Sarp S, Sarkar R, Soliman W.Eur J Haematol. 2025 Feb;114(2):293-302.
- Distance to CAR-T Treatment Center Does Not Impede Delivery. Tan XXS, Maltez MT, Mallick R, Hamelin L, McDiarmid S, Cieniak C, Granger M, Bredeson C, Kennah M, Atkins HL, Kekre N.Eur J Haematol. 2025 Feb;114(2):276-284.
- Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer. Connors C, Valente SA, ElSherif A, Escobar P, Chichura A, Kopicky L, Roesch E, Ritner J, McIntire P, Wu Y, Tu C, Lang JE.Ann Surg Oncol. 2025 Feb;32(2):912-921.
- Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction. Cho DH, Choi J, Youn JC, Kim MN, Lee CJ, Son JW, Yoo BS.ESC Heart Fail. 2025 Feb;12(1):603-612.
- The Opinion of Healthcare Professionals About a Proposed European Registry of Neuromodulation for Chronic Pain: An Online Survey. Goudman L, Rigoard P, Roulaud M, Slavin K, Russo M, Billot M, Moens M. 2025 Feb;28(2):362-368.
- Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Chandrakasan S, Allen CE, Bhatla D, Carter J, Chien M, Cooper R, Draper L, Eckstein OS, Hanna R, Hays JA, Hermiston ML, Hinson AP, Hobday PM, Isakoff MS, Jordan MB, Leiding JW, Modica R, Nakano TA, Oladapo A, Patel SA, Pednekar P, Riskalla M, Sarangi SN, Satwani P, Tandra A, Walkovich KJ, Yee JD, Zoref-Lorenz A, Behrens EM; REAL‐HLH investigators. Arthritis Rheumatol. 2025 Feb;77(2):226-238.
- Addressing immortal time bias in precision medicine: Practical guidance and methods development. Weymann D, Krebs E, Regier DA.Health Serv Res. 2025 Feb;60(1):e14376.
- Evaluating the timing of triple therapy initiation for the treatment of asthma in Japan: prompt versus delayed. Requena G, Wood R, Ito R, Wild R, Mita C, Payne P, Mukai I, Castillo CM, Gelwicks S, Siddiqui R, Noorduyn SG, Oga T.J Asthma. 2025 Feb;62(2):216-225.
- COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. Kowdley KV, Hirschfield GM, Coombs C, Malecha ES, Bessonova L, Li J, Rathnayaka N, Mells G, Jones DE, Trivedi PJ, Hansen BE, Smith R, Wason J, Hiu S, Kareithi DN, Mason AL, Bowlus CL, Muller K, Carbone M, Berenguer M, Milkiewicz P, Adekunle F, Villamil A. Am J Gastroenterol. 2025 Feb 1;120(2):390-400.
- Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis. Bittermann T, Yagan L, Kathawate RG, Weinberg EM, Peyster EG, Lewis JD, Levy C, Goldberg DS. 2025 Feb 1;81(2):423-435.
- Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study. Stephan C, Spinner CD, Rieke A, Christensen S, Mauss S, Schreiber S, Albuquerque B, Heinzkill M, Ramroth H, Stellbrink HJ. HIV Med. 2025 Feb;26(2):239-251.
- US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Eugeni P, Rooney ME, Saikali NP, Niu Z, Driessen MT, Krasenbaum LJ, Carr K, Seminerio MJ, McVige JW. Adv Ther. 2025 Feb;42(2):1207-1221.
- Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI). Baptist AP, Germain G, Klimek J, Laliberté F, Schell RC, Forero-Schwanhaeuser S, Moore A, Noorduyn SG, Paczkowski R. Adv Ther. 2025 Feb;42(2):1061-1074.
- Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes from Japanese Payer Perspective. Igarashi A, Ohara K, Matsuda H, Morii J, Jagannathan S, Filomeno R. Adv Ther. 2025 Feb;42(2):995-1008.
- Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis. Rudofsky G, Menzen M, Potier L, Catarig AM, Clark A, Priyadarshini P, Abreu C. Adv Ther. 2025 Feb;42(2):788-800.
- Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data. Young C, Lee LY, DiRocco KK, Germain G, Klimek J, Laliberté F, Lejeune D, Noorduyn SG, Paczkowski R. Adv Ther. 2025 Feb;42(2):830-848.
- Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors. Mease PJ, Ferrante SA, Shiff NJ, Fitzgerald TP, Chakravarty SD, Walsh JA. Adv Ther. 2025 Feb;42(2):734-751.
- Real-world safety and efficacy of rADAMTS13 in the treatment of congenital thrombotic thrombocytopenic purpura in pediatric patients in Poland. Laguna P, Szczepanska M, Wojdalska M, Bobrowska H, Kulik J, Pietrys D, Balwierz W, Trembecka-Dubel E, Mlynarski W, Laguna A.J Thromb Haemost. 2025 Feb;23(2):635-640.
- Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Rocque GB, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Karuturi MS, Tripathy D. Breast Cancer Res Treat. 2025 Feb;209(3):613-627.
- Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real-world evidence. Jhu JY, Fang YW, Huang CY, Liou HH, Chen MT, Tsai MH. J Diabetes Investig. 2025 Feb;16(2):204-214.
- Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 2019. Chien YN, Lin LY, Lin YC, Hsieh YC, Tu SH, Chiou HY. Breast Cancer Res Treat. 2025 Feb;209(3):647-658.
- Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO). Khattri S, González-Cantero Á, Engin B, Dogra S, Murphy CA, Schuster C, Tsujimoto N, Martimianaki G, Lampropoulou A, Alsharafi A, Konicek B, Lauffer F. Adv Ther. 2025 Jan;42(1):233-245.
REVIEWS
- A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective. Kumar RMR, Joghee S. Curr Treat Options Oncol. 2025 Jan;26(1):1-13. Review
- Collaborative Real-World Evidence Among Regulators: Lessons and Perspectives. Beck AE, Kampman M, Huynh C, Simon C, Plueschke K, Cohet C, Verpillat P, Robinson K, Arlett P. Clin Pharmacol Ther. 2025 Feb;117(2):368-373. Review.
- Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice. Pianko MJ, Mian HS, Schoenbeck KL, Wildes TM.Leuk Lymphoma. 2025 Feb;66(2):190-203. Review.
- Malignant melanoma in Portuguese adult population: a scoping review of the real-world evidence. Gouveia E, de Sousa RT, Aguiar SI, Gírio A, Costa I, Dionísio MR, Moital I.Clin Transl Oncol. 2025 Feb;27(2):770-777. Review.
- The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review. Che Y, Duffield S, Gomes M. 2025 Feb;43(2):123-131. Review.
- Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice. Pianko MJ, Mian HS, Schoenbeck KL, Wildes TM. Leuk Lymphoma. 2025 Feb;66(2):190-203. Review.
- A methodological review identified several options for utilizing registries for randomized controlled trials. Urban L, Haller N, Pieper D, Mathes T.J Clin Epidemiol. 2025 Feb;178:111614.